Mark Doerr

Mark Doerr is a principal and senior research analyst at Tech Insider covering medical technology companies with a focus on cardiovascular and related therapeutic technology. Mark leverages his prior experience as the director of marketing and business development at a medical device company, along with an extensive network of physician and industry relationships, to provide a unique perspective on the medtech sector. Prior to joining Tech Insider in 2011 he covered medical technology for four years at Craig-Hallum Capital, and has in total 20 years of financial and medtech industry experience.

After-Hours Movers: Tesla (TSLA) Edges Higher After Detailing Convertible Offering; NKTR, HDSN, ISIG

Tesla (NASDAQ:TSLA) edges higher in after-hours trading, having hit another record high, at $265, in Wednesday’s regular trading session, after it files to sell $1.6 billion in convertible debt. Of the total offering, the luxury electric car maker will offer $800 million aggregate principal amount of convertible senior notes due 2019 and $800 million aggregate…

Read More

Autodesk (NASDAQ:ADSK) Climbs After-Hours After Beating Estimates; (NASDAQ:PEIX), (NYSE:WMB)

Autodesk Inc. (NASDAQ:ADSK) rose 4.2% in extended trading after reporting earnings that beat analyst estimates. The software company’s Q4 earnings fell 25% from a year earlier to $0.40 a share, beating the Capital IQ estimate of $0.34. Revenue slipped 3.4% from a year earlier $586.6 million, beating the consensus estimate of $571 million. Autodesk estimated…

Read More

Transocean (NYSE: RIG) and Dollar Tree (NASDAQ: DLTR) Highlight After-Market Earnings

Transocean Ltd. (NYSE: RIG) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in RIG indicates that the price change in the extended hours…

Read More

Notable Analyst Updates – Spectranetics, HSBC, Verizon, New Home Company, Real Page

Sprectranetics (NASDAQ:SPNC) rose 10% and touched a 52-week high after the company said late Monday its trial using laser atherectomy to treat patients suffering from peripheral artery disease (PAD) had achieved statistical endpoints. Separately, Stifel Nicolas repeated its Buy recommendation on the stock and raised its price target to $30 from $24. Spectranetics, a maker…

Read More